Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2024-05-23 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
US FDA Grants Orphan Drug Designation to PYC Drug Candidate 3 pages 240.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PYC Therapeutics has received Orphan Drug Designation (ODD) from the US FDA for a drug candidate. It discusses the drug development pipeline, clinical trial plans, and regulatory benefits of the designation. There are no financial statements, earnings data, or detailed financial analysis. The document is an update on regulatory status and clinical development progress, typical of a Capital/Financing Update or Regulatory Filing. However, since it focuses on regulatory approval status and clinical trial commencement rather than fundraising or capital structure changes, it fits best under Regulatory Filings (RNS). The document is about 5939 characters, which is not a brief announcement of a report publication but a substantive announcement of regulatory progress. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-05-23 English
Notification regarding unquoted securities - PYC 6 pages 19.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options under an employee incentive scheme by PYC Therapeutics Limited. It includes specifics such as the number of securities issued, exercise price, expiry date, and references to ASX listing rules. The content is a formal announcement of a securities issuance event, specifically unquoted options, which fits the category of a share issue or capital change. There is no financial statement or report content, nor is it a regulatory certification or voting result. Therefore, the document is best classified as a Share Issue/Capital Change announcement.
2024-05-22 English
Issue of Options 4 pages 280.0KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 23 May 2024 regarding the issue of options by PYC Therapeutics. It includes detailed terms and conditions of the options issued, such as exercise price, expiry date, vesting conditions, transfer restrictions, and other related information. The document references an Appendix 3G lodged on the same date, which is a notification form related to the issue of unquoted equity securities. The content is focused on the issuance of options (a form of share-based compensation or capital raising) and does not contain financial statements, earnings data, or management discussion of financial results. It is not a full financial report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The document is best classified as a Capital/Financing Update (CAP) because it provides an update on the company's capital structure through the issuance of options.
2024-05-22 English
Change of Director's Interest Notice 2 pages 276.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the change (off-market trade), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. The document length is 3278 characters, which is typical for such notices. There is no indication that this is a full financial report, audit, or other types of filings. Therefore, the correct classification is Director's Dealing (DIRS).
2024-05-16 English
Change in substantial holding 3 pages 235.6KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a "Notice of change of interests of substantial holder." It details changes in voting power and relevant interests of a substantial shareholder in PYC Therapeutics Limited, including dates and share quantities. This type of filing is a regulatory notification about changes in major shareholdings, not a financial report or management announcement. It matches the definition of a Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a report publication notice but the actual notification form.
2024-05-16 English
RP11 Clinical Trial Dosing Completed in Cohort 4 4 pages 445.8KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 16 May 2024 from PYC Therapeutics about the completion of dosing in a clinical trial cohort for a drug candidate targeting Retinitis Pigmentosa type 11 (RP11). It provides detailed information about the clinical trial phases, drug candidate development, and future plans for further trials and regulatory submissions. The content focuses on clinical trial updates and drug development progress rather than financial results, management changes, or regulatory filings. It is not a full financial report, earnings release, or management discussion. The document is a clinical trial update announcement, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or report publication announcement since it contains substantive information about the clinical trial progress. Given the nature of the content, the best fitting category is Regulatory Filings (RNS) as a general announcement of clinical trial progress and company development updates that do not fit other specific categories.
2024-05-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.